Animal Data

To date Satiogen has completed 18 preclinical studies, the goals of which were to demonstrate the metabolic effects of targeting colorectal TGR5 receptors with bile acid and to build the company’s patent estate.  Following are snapshots of the results:

Cumulative food intake is reduced in rats rectally instilled with taurocholate-containing gel (“TCA” dotted lines) and control rats (solid lines).  The effect of the bile acid was highly statistically significant:

There is a dose response for the effect of rectal bile acid instillation on cumulative food intake over 1-24 hours in overnight-fasted Sprague Dawley rats:

An inhibitor of bile acid transport (264W94 by Glaxo) lowers plasma glucose levels in diabetic mice in a dose dependent manner and with or without a DPP4 inhibitor (JANUVIA):

The effects of inhibiting bile acid transport with 264W94 are of similar magnitude to subcutaneous injections of a GLP-1 agonist, and second inhibitor of bile acid transport (SC-435 by Pfizer) demonstrated similar effects:

Note:  The comparisons of bile acid inhibition to GLP-1 agonism are for the purpose of providing perspective on the relative magnitudes of the effects.  These are separate experiments and are not directly comparable for peer-reviewed presentations.